Olon Constructs Fermentation Facility in Italy
Olon began construction of a GMP facility for biologic APIs in Capua, Italy.
Olon SpA, an API contract development and manufacturing organization (CDMO) and generics supplier, began construction on a new GMP manufacturing facility at its microbial CDMO facility located in Capua, Italy, according to a July 24, 2019 press release.
"I am pleased to announce the start of this GMP capacity expansion just within six months after the acquisition of Capua BioServices. This truly confirms the real opportunity to accelerate growth in Olon's CDMO service positioning and to be recognized as European Leader in the CDMO of microbial fermentation," said Paolo Tubertini, CEO of Olon, in the press release.
The construction of this new GMP facility is associated with a long-term strategic partnership with a large pharmaceutical company. The engineering project is designed to support the manufacture of multiple products, up to commercial scale.
Olon is headquartered in Milan, Italy and has 11 manufacturing facilities in Europe (Italy and Spain), the US (Concord, OH), and India (Mahad).
Source: Olon
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
